10 Jan 2020 15:45
10 January 2020
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings and Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following share dealings by Directors:
Peter Allen, Chairman, exercised an option to acquire 173,421 new ordinary shares of £0.05 each ("Ordinary Shares") at a price of £0.002 per Ordinary Share and acquired 70,500 Ordinary Shares at a price of 28.4 pence per Ordinary Share. Following the transactions Peter Allen has a total interest of 413,365 Ordinary Shares, representing 0.5% of the enlarged total voting rights in the Company.
Sam Williams, Non-Executive Director, acquired 33,000 Ordinary Shares at a price of 28.5 pence per Ordinary Share. Following the transaction Sam Williams has a total interest of 85,248 Ordinary Shares, representing 0.1% of the enlarged total voting rights in the Company.
John Goddard, Non-Executive Director, was issued and allotted 12,326 new Ordinary Shares at an effective price of nil pence per Ordinary Share as part of a pre-existing arrangement whereby he receives shares in the Company in lieu of part of his Non-executive director fees, issued from the Company's Employee Benefit Trust. He also acquired 35,211 Ordinary Shares at a price of 28.4 pence per Ordinary Share.
Additionally, for tax planning purposes, John Goddard sold 28,526 Ordinary Shares at a price of 27.0 pence per Ordinary Share and acquired 28,316 Ordinary Shares at a price of 27.2 pence per Ordinary Share.
Following the transactions above John Goddard has a total interest of 175,626 Ordinary Shares, representing 0.2% of the enlarged total voting rights in the Company.
In addition to the above, a further 4,800 new Ordinary Shares will be issued as a result of an exercise of options under the Company's Long-Term Incentive Plan ("LTIP") by an employee of the Company.
As a result of the transactions above, in aggregate 190,547 new Ordinary Shares (the "New Ordinary Shares") are being issued.
Application will be made for admission of the New Ordinary Shares, which is anticipated to occur at 8:00am on Friday 17 January 2020 ("Admission"). The New Ordinary Shares rank pari passu with the existing shares of the Company. Following issue of the New Ordinary Shares, the Company's issued ordinary share capital consists of 86,725,987 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights is 86,725,987.
The above figure of 86,725,987 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Details of the full notifications received by the Company are set out below:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Peter Allen | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chairman | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
0.002 0.284 | 173,421 70,500 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | 243,921 | ||||
- Price | £20,368.84 | ||||
e)
| Date of the transaction
| 9 January 2020 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Sam Williams | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
0.285 | 33,000 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 10 January 2020 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| John Goddard | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Sale and acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Nil 0.284 0.27 0.272 | 12,326 35,211 28,526 28,316 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | 104,379 | ||||
- Price | £25,403.89 | ||||
e)
| Date of the transaction
| 10 January 2020 | |||
f)
| Place of the transaction
| XLON | |||
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Michael Boot | |
Healthcare Equity Sales: Andrew Keith | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk